^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy

Excerpt:
...Patients with RICTOR amplification or overexpression through the VIKTORY trial....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy

Excerpt:
...Patients with RICTOR amplification through NGS....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

Excerpt:
MTT proliferation assays showed increased sensitivity to the dual mTORC1/2 inhibitor AZD2014 and the dual PI3K/mTOR compound BEZ235 (Figure 2B)...among the various inhibitors tested, AZD2014 showed the most potent inhibitory effect onRICTOR-amplified GC PDCs.
DOI:
10.1093/annonc/mdw669